Antivirals Market Analysis: By Type (Hepatitis-C, HIV, Herpes, Hepatitis-B, Influenza Other Antivirals); By Action (DNA polymerase inhibitors, NS3 Protease inhibitors, Reverse transcriptase inhibitors and OthersWith Forecast (2016-2021)

  • ID: 3919961
  • Report
  • 147 pages
  • IndustryARC
1 of 3
Antivirals are drugs that are used to treat viral infections. While a majority of antivirals are used for treating specific viral infections, there are a few broad-spectrum antivirals to treat other viral infections. As opposed to antibiotics that actually destroy the target pathogen, antivirals only inhibit the growth of the pathogen. Antivirals have the advantage of not causing any side effects and focus on inibiting the replication of the virus. An increase in the disease afflicted population across the globe is one of the major drivers for this market. Apart from this, increasing levels of awareness coupled with the launch of newer and more effective drugs, this market has tremendous opportunities in emerging economies. The antiviral market is expected to grow at a steady and healthy growth rate till the end of the forecast period considered in this report. Expiry of patents is another factor providing opportunities for this market. Factors that include government policies can prove to be challenging factors in this market.

The report also provides an exhaustive overview of antiviral research and development pipeline. A huge amount of research and development is underway to extend the range of antivirals to treat other pathogens. Also, with the tendency of viruses to mutate and become drug resistant, the need of the hour is to develop and refresh the pipeline of antivirals with new therapies. A section on patent analysis is also included.

Antivirals Market

Antiviral drugs are used in the treatment of HIV, herpes viruses, the hepatitis B and C viruses, and influenza A and B viruses. The global antivirals market is expected to be dominated by HIV antivirals. According to the WHO and UNAIDS estimates, 36.7 million people were living with HIV globally at the end of 2015. In 2015, approximately 2.1 million people became newly infected and 1.1 million died of HIV-related causes.

The Antivirals market can be segmented on the basis of type as:
HIV Antivirals
Hepatitis-C Antivirals
Herpes Antivirals
Influenza Antivirals
Hepatitis-B Antivirals
Other Antivirals

In terms of actions, the Antivirals market has been segmented across the following:
DNA polymerase inhibitors
NS3 Protease inhibitors
Reverse transcriptase inhibitors
The market has been segmented based on the following geographies:
North America
South America
Middle East

Following are just a few of the companies that are operating in the Antivirals market:
GlaxoSmithKline plc
Merck & Co
Johnson and Johnson
Novartis International AG
Gilead Sciences Inc
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 3
1. Antivirals Market Overview
2. Executive Summary
3. Antivirals Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. Antivirals Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of the Antivirals Market
4.4.1. Power of Suppliers
4.4.2. Power of Customers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitution
4.4.5. Degree of Competition
5. Antivirals Market - Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Antivirals Market By Type
6.1. Hepatitis-C antivirals
6.2. HIV antivirals
6.3. Herpes antivirals
6.4. Hepatitis-B antivirals
6.5. Influenza antivirals
6.6. Others
7. Antivirals Market By Actions
7.1. DNA polymerase inhibitors
7.2. NS3 Protease inhibitors
7.3. Reverse transcriptase inhibitors
7.4. Others
8. Antivirals Market By Geography
8.1. Introduction
8.2. Global Study
8.3. Americas
8.3.1. North America
8.3.2. Brazil
8.3.3. Argentina
8.3.4. Others
8.4. Europe
8.4.1. U.K.
8.4.2. France
8.4.3. Germany
8.4.4. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. Others
8.6. ROW
9. Antivirals Market Entropy
9.1. New Product Launches
9.2. M&As, Collaborations, JVs and Partnerships
10. Company Profiles
10.1. Novartis AG
10.2. Gilead Sciences Inc.
10.3. Merck
10.4. Johnson and Johnson
10.5. GlaxoSmithKline
10.6. Abbott Laboratories
10.7. AstraZeneca AB
10.8. BoehringerIngelheim Corporation
10.9. Schering-Plough
10.10. Roche

"*Financials would be provided on a best efforts basis for private companies"
11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Research Methodology
11.4. Bibliography
11.5. Compilation of Expert Insights
11.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown